Alphyn’s initial product is expected to be the first product to treat all the problems of Atopic Dermatitis (AD), both the immune response and bacterial problems, including the AD problems caused by the drug resistant MRSA bacteria.
AD greatly impacts the quality of life for 32 million Americans each year.1 A multi-center, vehicle-controlled, randomized and double-blind Phase 2a clinical trial of AB-101a enrolling adult and pediatric patients ages 2 and up for mild to moderate AD is currently underway. The global AD market is estimated at $18.1 billion growing to $34.1 billion by 2026.2 Fully 70% of AD sufferers report unbearable itch with 55% reporting their AD is not under control.1 AD significantly affects lifestyle resulting in 5.9 million lost workdays each year.1 There is a 160% increase in the risk of suicide for AD patients.3 A solution is clearly needed. AB-101a’s test results and mechanisms of action are directly targeted to be the answer.